Baxter
This article was originally published in The Gray Sheet
Executive Summary
Board of directors authorizes repurchase up to 12 mil. shares of common stock "for use in employee stock option, stock repurchase and other benefit plans, and other authorized corporate purposes." The repurchase plan extends a November 1990 board authorization for the purchase of up to 13.5 mil. shares. Baxter has already bought back 12.5 mil. shares under the 1990 and prior grants of authority.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.